Clinical Trials Sponsored by Precigen, Inc

Total 35642 results

Precigen, Inc

Recruiting

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Precigen, Inc

Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditions

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

Obesity | Overweight | Nicotine Dependence

United States
Orexigen Therapeutics, Inc

Completed

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Obesity

United States
Precigen, Inc
National Cancer Institute (NCI)

Recruiting

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical Cancer | HPV-Related Malignancy | HPV-Related Carcinoma

United States
Orexigen Therapeutics, Inc

Terminated

Naltrexone/Bupropion Cardiovascular Outcomes Study

Cardiovascular Diseases | Obesity

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Heart Repolarization

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Healthy Subjects
Orexigen Therapeutics, Inc

Completed

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Obesity

United States
Orexigen Therapeutics, Inc

Completed

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Obesity

United States
Precigen, Inc
National Cancer Institute (NCI)

Active, not recruiting

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Papillomavirus Infections | Recurrent Respiratory Papillomatosis | Papillomaviridae

United States
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Healthy

United States
Orexigen Therapeutics, Inc

Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight

United States
Orexigen Therapeutics, Inc

Terminated

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

United States
Orexigen Therapeutics, Inc

Terminated

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Depression

United States
Orexigen Therapeutics, Inc

Completed

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

Obesity

United States
Triple-Gene, LLC
Intrexon Corporation; Precigen, Inc

Completed

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Cardiovascular Diseases | Heart Failure | Heart-Assist Device

United States
Oslo University Hospital
Orexigen Therapeutics, Inc

Withdrawn

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Obesity
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
Precise Dx, Inc.
The Cleveland Clinic

Not yet recruiting

Decision Impact Study of PreciseDx Breast (PDxBRUTILITY)

Breast Cancer
Precigen Actobio T1D, LLC
TFS Trial Form Support; Intrexon Actobiotics NV, d/b/a Precigen Actobio

Completed

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

Diabetes Mellitus, Type 1

United States, Belgium
Wuhan Recogen Biotechnology Co., Ltd.

Withdrawn

Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine

COVID-19 Pandemic
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Wuhan Rhegen Biotechnology Co., Ltd.
Shenzhen Rhegen Biotechnology Co., Ltd.; Wuhan Recogen Biotechnology Co., Ltd.

Withdrawn

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

COVID-19 Pandemic
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
Novan, Inc.
Synteract, Inc.; Therapeutics, Inc.

Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

Molluscum Contagiosum

United States
Vitality in Aging Research Group, Inc.

Withdrawn

VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

Aging
In-Home Addiction Treatment Institute, Inc.

Suspended

Effects of In-Home Addiction Treatment for First Responders

Substance Use Disorders

United States
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc; Immune-Onc Therapeutics; NiKang Therapeutics...

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Mylan Technologies Inc.
Mylan Inc.

Active, not recruiting

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Contraception

United States, Canada, Puerto Rico
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
SerenaGroup, Inc.
DrySee, Inc

Completed

A Comparison Between Two Post-operative Dressings (DrySee)

Surgical Incision

United States

Clinical Trials Sponsored by Precigen, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations